Product-focused roadmap shows how MSC secretomes can become scalable, standardized, GMP-ready biotherapeutics.

The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

Compared with an injection of saline placebo, a single intra-articular injection of autologous adipose-derived mesenchymal stromal cells showed no significant improvement in pain or function scores in ...

Researchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to quietly gain dominance with age. Reprogrammed stromal cells and interferon ...

Lancet Phase 1 study finds in-womb stem cell therapy feasible and safe in spina bifida, supporting expansion to a larger clinical trial.